Q-omics provides the consensus-scored MIR5692C2 profile across patient tissues and cancer cell-line models. MIR5692C2 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, MIR5692C2 is differentially expressed in 4, with the highest sampling consensus in KIRC. Additionally, MIR5692C2 RNA expression shows 13,146 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight COAD, KIRC, and LAML as cancer lineages where MIR5692C2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR5692C2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR5692C2 survival associations across molecular data types. MIR5692C2 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR5692C2 RNA expression–survival associations across cancer types. High MIR5692C2 expression shows unfavorable associations in COAD, LIHC, LUSC, UCEC and STAD, but favorable associations in BLCA. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for MIR5692C2 RNA expression.
This table summarizes MIR5692C2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR5692C2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR5692C2 shows lower tumor expression in READ and THCA and higher tumor expression in KIRC and KIRP. The KIRC box plot shows higher MIR5692C2 RNA expression in tumor versus normal tissue (log2 FC = +0.215, t-test p = .008).
This table shows molecular features associated with MIR5692C2 in patient tissues and cancer cell lines. In patient samples, MIR5692C2 shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set.
